ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Sevilla, AN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Sevilla, AN, ESP:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

Sevilla, Spain and 51 other locations

Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: revumenib
Drug: cobicistat

Phase 1, Phase 2

Syndax Pharmaceuticals
Syndax Pharmaceuticals

Seville, Spain and 47 other locations

a standard of care for patients with newly diagnosed acute myeloid leukemia not eligible for intensive chemotherapy (thus not eligible for a...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Azacitidine
Drug: Pevonedistat

Phase 3

PETHEMA Foundation

Sevilla, Spain and 63 other locations

The study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia...

Enrolling
B Cell Precursor Acute Lymphoblastic Leukemia
Drug: Blinatumomab

Phase 1, Phase 2

Amgen
Amgen

Sevilla, Andalucía, Spain and 41 other locations

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) or AML secondary to prior m...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine

Phase 3

Celgene
Celgene

Sevilla, Spain and 222 other locations

The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximu...

Enrolling
Acute Myeloid Leukemia Refractory
Myelodysplastic Syndrome Acute Myeloid Leukemia
Drug: AB8939
Drug: Azacitidine

Phase 1, Phase 2

AB Science
AB Science

Sevilla, Spain and 9 other locations

syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who are not eligible for intensive chemotherapy or hematopoietic...

Active, not recruiting
Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes
Drug: Placebo
Drug: Azacitidine

Phase 3

Novartis
Novartis

Sevilla, Andalucia, Spain and 148 other locations

in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myel...

Enrolling
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Drug: CC-91633

Phase 1

Celgene
Celgene

Sevilla, Spain and 28 other locations

The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely co...

Active, not recruiting
Chronic Lymphocytic Leukemia
Non Hodgkin Lymphoma
Drug: tafasitamab
Drug: parsaclisib

Phase 1, Phase 2

Incyte
Incyte

Sevilla, Spain and 49 other locations

or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib versus asciminib 80mg in pre-treated patients with Chronic Myeloid Leukemia...

Active, not recruiting
Chronic Myelogenous Leukemia
Leukemia, Myeloid Chronic
Drug: Asciminib add-on
Drug: Nilotinib

Phase 2

Novartis
Novartis

Sevilla, Andalucia, Spain and 28 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems